A number of other research analysts also recently issued reports on GXI. Hauck & Aufhaeuser set a €60.00 ($69.77) price objective on Gerresheimer and gave the company a sell rating in a research note on Monday, October 8th. Kepler Capital Markets set a €65.00 ($75.58) price objective on Gerresheimer and gave the company a sell rating in a research note on Thursday, July 12th. Commerzbank set a €68.00 ($79.07) price objective on Gerresheimer and gave the company a neutral rating in a research note on Thursday, June 21st. HSBC set a €67.00 ($77.91) price objective on Gerresheimer and gave the company a neutral rating in a research note on Monday, July 16th. Finally, JPMorgan Chase & Co. set a €72.00 ($83.72) target price on Gerresheimer and gave the company a neutral rating in a research report on Tuesday, October 9th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. Gerresheimer presently has an average rating of Hold and a consensus target price of €71.67 ($83.33).
Shares of ETR:GXI opened at €61.50 ($71.51) on Thursday. Gerresheimer has a 1 year low of €59.97 ($69.73) and a 1 year high of €78.25 ($90.99).
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.